---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025443"
form_type: "8-K"
ticker: null
cik: "0001169987"
company_name: "HTG MOLECULAR DIAGNOSTICS, INC"
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:41:10.732591+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HTG Molecular receives Nasdaq delisting notice for stockholders' equity below $2.5M

## Summary
- Nasdaq notified HTG Molecular on Nov 18, 2022 for non-compliance due to stockholders' equity falling below $2.5M as of Sept 30, 2022.
- Company has 45 calendar days, until Jan 2, 2023, to submit a plan to regain compliance with Nasdaq Rule 5550(b).
- If plan accepted, Nasdaq may grant up to 180-day extension from Notice date for evidence of compliance.
- No assurance that the Company will be able to regain compliance with the continued listing standard.

## SEC filing metadata
- accession: 0000950170-22-025443
- form_type: 8-K
- cik: 0001169987
- company_name: HTG MOLECULAR DIAGNOSTICS, INC
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1169987/000095017022025443/0000950170-22-025443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1169987/000095017022025443/htgm-20221118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025443
- JSON: https://secwatch.observer/filing/0000950170-22-025443.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025443.txt

## Key facts
- Listing & Compliance Notices
  HTG MOLECULAR DIAGNOSTICS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)
  source text: November 18, 2022, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”). Pursuant to the Notice and Nasdaq rules, the Company has 45 calendar days, or until January 2, 2023, to submit a plan to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1169987/000095017022025443/0000950170-22-025443-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.